Latest Sanofi Stories
The increased adoption of insulin pens and growing number of diagnosed diabetics will drive the US market for modern insulin to over $17 billion by 2020, reports iData Research. Vancouver,
Seven-fold lower incidence of VTE in patients treated with ISIS-FXI Rx compared with enoxaparin CARLSBAD, Calif., Dec. 7, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc.
NEW YORK, Dec. 4, 2014 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Sanofi.
ReportsnReports.com adds Hepatitis B Global Clinical Trials Review H2 2014 to its store.
Company Appoints Director of IT Services, Continues to Chart Record Growth and Momentum in Technology Sector ATLANTA, Dec.
Sanofi Commitment to Research and Develop TB Treatments, Diagnostics and Vaccines Spans More than 50 Years BRIDGEWATER, N.J., Dec.
TARRYTOWN, N.Y. and PARIS, Nov. 20, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S.
All six trials met primary efficacy endpoint TARRYTOWN, N.Y. and PARIS, Nov. 19, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc.
- Large; stout; burly.